Major publication validates CTVQ for lung surgery
Open PDF
| Stock | 4DMEDICAL Ltd (4DX.ASX) |
|---|---|
| Release Time | 19 May 2026, 9:51 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
4DMedical's CT:VQ Validated for Lung Surgery in Major Study
Key Points
- Study published in AJRCCM validates CT:VQ for lung surgery
- CT:VQ-guided selection shows 76% response rate to surgery
- Improved patient selection strengthens LVRS economics for hospitals
Full Summary
4DMedical Limited, a global leader in respiratory imaging technology, announces the publication of a clinical study in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), validating the use of its CT:VQ technology for lung volume reduction surgery (LVRS). The study found that CT:VQ-guided selection resulted in a 76% response rate to surgery, compared to the current 46% rate. This improved patient selection strengthens the economics of LVRS programs for hospitals by focusing high-value surgical resources on patients most likely to benefit.
Guidance
null
Outlook
null
Sign in to get more information about the company, including guidance changes and other insights.
Sign In